Wells Fargo & Company Protara Therapeutics, Inc. Transaction History

Wells Fargo & Company

$410 Billion
Q1 2024

A detailed history of Wells Fargo & Company transactions in Protara Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 570 shares of TARA stock, worth $1,316. This represents 0.0% of its overall portfolio holdings.

Number of Shares

570

Previous 569 0.18%

Holding current value

$1,316

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.86 - $4.83 $1 - $4	1 Added 0.18%	570 $2,000
Q4 2023 Feb 09, 2024	BUY	$1.12 - $1.93 $4 - $7	4 Added 0.71%	569 $1,000
Q3 2023 Nov 13, 2023	BUY	$1.64 - $2.93 $3 - $5	2 Added 0.36%	565 $0
Q2 2023 Aug 15, 2023	BUY	$2.27 - $3.59 $6 - $10	3 Added 0.54%	563 $1,000
Q1 2023 May 12, 2023	BUY	$2.76 - $3.91 $2 - $3	1 Added 0.18%	560 $1,000

Q4 2022 Feb 13, 2023	BUY	$2.43 - $3.7 $2 - $3	1 Added 0.18%	559 $1,000
Q3 2022 Nov 14, 2022	SELL	$2.99 - $4.27 $23 - $34	-8 Reduced 1.41%	558 $1,000
Q2 2022 Aug 12, 2022	BUY	$2.8 - $5.33 $16 - $31	6 Added 1.07%	566 $1,000
Q3 2021 Nov 15, 2021	BUY	$6.38 - $9.3 $6 - $9	1 Added 0.18%	560 $3,000
Q2 2021 Aug 16, 2021	SELL	$8.68 - $16.99 $587,922 - $1.15 Million	-67,733 Reduced 99.18%	559 $6,000
Q1 2021 May 13, 2021	BUY	$13.75 - $23.86 $758,752 - $1.32 Million	55,182 Added 420.92%	68,292 $1.08 Million
Q4 2020 Feb 09, 2021	SELL	$16.97 - $25.34 $58,597 - $87,499	-3,453 Reduced 20.85%	13,110 $317,000
Q3 2020 Nov 05, 2020	BUY	$16.76 - $31.89 $130,728 - $248,742	7,800 Added 89.01%	16,563 $279,000
Q2 2020 Aug 13, 2020	BUY	$22.0 - $60.7 $192,786 - $531,914	8,763 New	8,763 $257,000

Others Institutions Holding TARA

# of Institutions

Shares Held

4.54M

Call Options Held

102K

Put Options Held

18.2K

View Full List

About Protara Therapeutics, Inc.

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $26M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

More about TARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Protara Therapeutics, Inc. Transaction History